Genetic and non-genetic factors responsible for antiplatelet effects of clopidogrel in Japanese patients undergoing coronary stent implantation: An algorithm to predict on-clopidogrel platelet reactivity
- 1 October 2014
- journal article
- research article
- Published by Elsevier in Thrombosis Research
- Vol. 134 (4) , 877-883
Abstract
No abstract availableKeywords
This publication has 48 references indexed in Scilit:
- Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry studyThe Lancet, 2013
- Recent advances in the pharmacogenetics of clopidogrelHuman Genetics, 2011
- Identification of the Human Cytochrome P450 Enzymes Involved in the Two Oxidative Steps in the Bioactivation of Clopidogrel to Its Pharmacologically Active MetaboliteDrug Metabolism and Disposition, 2010
- Common Variation in the Platelet Receptor P2RY12 Gene Is Associated With Residual On-Clopidogrel Platelet Reactivity in Patients Undergoing Elective Percutaneous Coronary InterventionsCirculation: Cardiovascular Genetics, 2009
- A population-based study of the drug interaction between proton pump inhibitors and clopidogrelCanadian Medical Association Journal, 2009
- Genetic Determinants of Response to Clopidogrel and Cardiovascular EventsNew England Journal of Medicine, 2009
- Impact of P-glycoprotein on clopidogrel absorptionClinical Pharmacology & Therapeutics, 2006
- Impaired platelet function in a patient with P2Y12 deficiency caused by a mutation in the translation initiation codonJournal of Thrombosis and Haemostasis, 2005
- Clinical Significance of the Cytochrome P450 2C19 Genetic PolymorphismClinical Pharmacokinetics, 2002
- A new look at the statistical model identificationIEEE Transactions on Automatic Control, 1974